Cargando…
Cabazitaxel-Loaded Nanocarriers for Cancer Therapy with Reduced Side Effects
Jevtana(®) is a micellar cabazitaxel (CBZ) solution that was approved for prostate cancer in 2010, and recently, this drug has been reported for breast cancer. The purpose of this study is to evaluate the mediated delivery of CBZ via liposomes and nanoparticles (NPs) for the treatment of breast canc...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6470818/ https://www.ncbi.nlm.nih.gov/pubmed/30934535 http://dx.doi.org/10.3390/pharmaceutics11030141 |